which drove the nail in the coffin for gene patents, and opened up BRCA testing to the entire industry. What are the benefits of the increased accuracy of Ambry’s tests? Within the commercial ...

“These findings demonstrate the value of collaborative research in advancing our understanding of BRCA2 ... genetic mutations. Ambry Genetics translates scientific research into clinically ...

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement. Directly after the Supreme Court announced its decision ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...

today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.